Products containing botulinum toxin type A (BoNTA) are popular for addressing patients' cosmetic and medical concerns. Current BoNTA products in the market had recommended treatment intervals of 12-16 weeks and require repeat visits to maintain therapeutic efficacy. DaxibotulinumtoxinA (DAXI) for injection is a novel neuromodulator with a unique formulation that may provide longer duration of action than those currently available. Here, we will review the literature on DAXI and provide an overview of the clinical formulation, mechanism of action, pivotal clinical trials, indications, safety profile, adverse events, and immunogenicity. DAXI has the potential to improve the management of both aesthetic and neuromuscular conditions. Long-term clinical data and further studies are needed to confirm the promising initial clinical data.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.